Stocktoria
SUTRO BIOPHARMA, INC. STRO
SUTRO BIOPHARMA, INC. (STRO) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $102.5M at a -186.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| STRO | SUTRO BIOPHARMA, INC. | 2/9 | — | — | +65.2% |
| IPSC | Century Therapeutics, Inc. | 3/9 | -6.53 | — | — |
| IBRX | ImmunityBio, Inc. | 4/9 | — | — | +668.3% |
| AGEN | AGENUS INC | 2/9 | — | — | +10.4% |
| FDMT | 4D Molecular Therapeutics, Inc. | 3/9 | 6.96 | — | — |
| ATRA | Atara Biotherapeutics, Inc. | 4/9 | — | 2.9 | -6.3% |
| MGTX | MeiraGTx Holdings plc | 2/9 | -14.65 | — | +144.6% |
About SUTRO BIOPHARMA, INC.
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
FAQ
Is STRO financially healthy?
SUTRO BIOPHARMA, INC.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does STRO pay a dividend?
No, SUTRO BIOPHARMA, INC. does not currently pay a dividend.
How profitable is STRO?
In FY2025, SUTRO BIOPHARMA, INC. had a net margin of -186.5%.
What is the analyst price target for STRO?
The average Wall-Street price target for SUTRO BIOPHARMA, INC. is $48.31, about 126.8% above the recent price, from 13 analysts.
Is STRO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on SUTRO BIOPHARMA, INC.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.